Pfizer, Inc.
PFE · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $62.58B | $63.63B | $50.91B | $91.79B | $73.64B | $41.65B | $40.91B | $40.83B |
| Cost of Revenue | $16.07B | $17.85B | $24.95B | $34.34B | $30.82B | $8.48B | $8.05B | $8.99B |
| Selling, General & Administrative | $13.79B | $14.73B | $14.77B | $13.68B | $12.70B | $11.60B | $12.73B | $12.61B |
| Interest Expense | $2.67B | $3.09B | $2.21B | $1.24B | $1.29B | $1.45B | $1.57B | $1.32B |
| Other Income / (Expense) | -$6.72B | -$4.39B | -$222.00M | -$1.06B | $4.88B | -$1.21B | -$3.50B | -$2.08B |
| Income Before Taxes | $7.52B | $8.02B | $1.06B | $34.73B | $24.31B | $7.04B | $11.32B | $3.59B |
| Provision for Income Taxes | -$266.00M | -$28.00M | -$1.11B | $3.33B | $1.85B | $370.00M | $583.00M | -$266.00M |
| Net Income | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | $9.16B | $16.03B | $11.15B |
| Basic EPS | $1.37 | $1.42 | $0.38 | $5.59 | $3.92 | $1.65 | $2.88 | $1.90 |
| Diluted EPS | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 | $1.63 | $2.82 | $1.87 |
| Basic Shares Outstanding | 5.68B | 5.66B | 5.64B | 5.61B | 5.60B | 5.55B | 5.57B | 5.87B |
| Diluted Shares Outstanding | 5.71B | 5.70B | 5.71B | 5.73B | 5.71B | 5.63B | 5.67B | 5.98B |
Analyst Estimates
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $2.98 | $2.88 | $3.10 | 10 | ↑1 ↓0 |
| Dec 2027 | $2.94 | $2.81 | $3.15 | 10 | ↑1 ↓0 |
| Dec 2028 | $2.45 | $2.28 | $2.75 | 4 | ↑0 ↓0 |
| Dec 2029 | $1.86 | $1.86 | $1.86 | 1 | ↑0 ↓0 |
